Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

Abstract

BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis.